NCT04195646 is a NA clinical trial of EndoVigilant CAD Software in Colo-rectal Cancer, sponsored by EndoVigilant Inc.

Who is sponsoring NCT04195646?

NCT04195646 is sponsored by EndoVigilant Inc.

What drugs are being tested in NCT04195646?

Interventions in NCT04195646: EndoVigilant CAD Software.

What condition does NCT04195646 study?

NCT04195646 studies Colo-rectal Cancer, Polyp of Colon, Adenomatous Polyps.

Is NCT04195646 still recruiting?

NCT04195646 is currently completed. Last updated 2 September 2021.

Last reviewed 2021-09-02 · How we verify

NCT04195646

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Computer Aided Detection of Polyps During Colonoscopy Procedures

Completed NA Last updated 2 September 2021

What this trial tests

NA trial testing EndoVigilant CAD Software in Colo-rectal Cancer in 300 participants. Completed in 28 February 2020.

Timeline

1 October 2019

Primary endpoint
15 February 2020

28 February 2020

Quick facts

Lead sponsor	EndoVigilant Inc
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	device feasibility
Enrollment	300
Start date	1 October 2019
Primary completion	15 February 2020
Estimated completion	28 February 2020
Sites	2 locations across United States

Drugs / interventions tested

EndoVigilant CAD Software

Conditions studied

Colo-rectal Cancer — all drugs for Colo-rectal Cancer →
Polyp of Colon — all drugs for Polyp of Colon →
Adenomatous Polyps — all drugs for Adenomatous Polyps →

Sponsor

EndoVigilant Inc

Who can join

Adults 18 to 85, any sex, with Colo-rectal Cancer or Polyp of Colon. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The focus of the study is to evaluate impact on Adenomas Per Colonoscopy (APC) with a Computer Aided Detection (CAD) software assisting the gastroenterologist during a colonoscopy procedure.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Artificial Intelligence in Oncology: A 10-Year ClinicalTrials.gov-Based Analysis Across the Cancer Control Continuum.
Verma H, Mistry S, Jayam KV, Shrestha P, et al · · 2025 · PMID 41228330 · DOI 10.3390/cancers17213537

Verify or expand the search:

Other recruiting trials for Colo-rectal Cancer

Currently open trials in the same condition.

NCT06645015 — The AIDPRO-CRC Trial · NA · recruiting
NCT07145255 — Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors · Phase 1, PHASE2 · recruiting
NCT07085169 — Low-dose Trifluridine/Tipiracil With Bevacizumab in mCRC · Phase 2 · recruiting
NCT06880055 — Shield Post-Approval Study Protocol · recruiting
NCT06905925 — The Effect of the Training Program Given to Permanent Colostomy Patients on Self-efficacy · NA · recruiting

Other EndoVigilant Inc trials

Trials by the same sponsor.

NCT04555135 — A Clinical Study To Measure The Effect Of Use Of Artificial Intelligence (AI) Enabled Computer Aided Detection (CADe) As · NA · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04195646 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by EndoVigilant Inc
Last refreshed: 2 September 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04195646.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing